TARRYTOWN, N.Y., Nov. 28 EpiCept Corporation(Nasdaq and OMX Nordic Exchange: EPCT) today announced that Jack Talley,President and CEO, will present a company overview at the BMO Capital MarketsFocus on Healthcare Conference on December 5, 2007 at 11:00 a.m. Eastern Time.The conference will be held at The Millennium Broadway Hotel in New York Cityon December 4th and 5th. Mr. Talley will present a company overview.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
The presentation will be available live via webcast on December 5, 2007.The webcast can be accessed by visiting the Company's website atwww.epicept.com. A replay of the presentation will be available following theevent.
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. TheCompany has a staged portfolio of pharmaceutical product candidates withseveral pain therapies in late-stage clinical trials, and a lead oncologycompound (for acute myeloid leukemia, or AML) with demonstrated efficacy in aPhase III trial; a marketing authorization application for this compound hasbeen submitted in Europe. EpiCept is based in Tarrytown, N.Y., and itsresearch and development team in San Diego is pursuing a drug discoveryprogram focused on novel approaches to apoptosis.
This news release and any oral statements made with respect to theinformation contained in this news release, contains forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995. Such forward-looking statements include statements which expressplans, anticipation, intent, contingency, goals, targets, future developmentand are otherwise not statements of historical fact. These statements arebased on EpiCept's current expectations and are subject to risks anduncertainties that could cause actual results or developments to be materiallydifferent from historical results or from any future results expressed orimplied by such forward-looking statements. Factors that may cause actualresults or developments to differ materially include: the risk that Ceplenewill not receive regulatory approval or marketing authorization in the EU orthat Ceplene, if approved, will not achieve significant commercial success,the risk that Myriad's development of Azixa(TM)* will not be successful, therisk that Azixa will not receive regulatory approval or achieve significantcommercial success, the risk that EpiCept will not receive any significantpayments under its agreement with Myriad, the risk that the development of theCompany's other apoptosis product candidates will not be successful, the riskthat its ASAP technology will not yield any successful product candidates, therisk that clinical trials for NP-1 or EPC 2407 will not be successful, thatNP-1 or EPC 2407 will not receive regulatory approval or achieve significantcommercial success, the risk that the Company's other product candidates thatappeared promising in early research and clinical trials do not demonstratesafety and/or efficacy in larger-scale or later stage clinical trials, therisk that EpiCept will not obtain approval to market any of its productcandidates, the risks associated with reliance on additional outside financingto meet its capital requirements, the risks associated with dependence uponkey personnel, the risks associated with reliance on collaborative partnersand others for further clinical trials, development, manufacturing andcommercialization of its product candidates; the cost, delays anduncertainties associated with its scientific research, product development,clinical trials and regulatory approval process; its history of operatinglosses since inception; competition; litigation; risks associated with priormaterial weaknesses in internal controls; and risks associated with theCompany's ability to protect its intellectual property.